HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
INMD
InMode Ltd.
INMD's fundamentals are weak: its operating margin fell 10 points to 18% and earnings per share fell 50%, though it turned 23% of its revenue into free cash flow. At 11x earnings, it's trading below its usual 15x. Analysts expect earnings to hold roughly steady.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
INMD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Strong |
INMD's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
INMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9x | $11.06 | -16% |
| Forward | 9.8x | $13.19 | — |
| Current | 11x | $13.19 | — |
| Fair | 15x | $18.29 | +39% |
| Expensive | 35x | $43.04 | +226% |
Historical ranges are pointers, not guarantees.
INMD's PE is in its fair range at 11x. On analysts' estimates for next year's earnings, today's price would be 9.8x, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
INMD Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Stable | |
| Stable | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect INMD's profitability to weaken, with its earnings and revenue holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
INMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.35 | +10% |
| Q2 2026 | $1.23 | -50% |
| Q2 2025 | $2.47 | +42% |
| Q2 2024 | $1.74 | -19% |
| Q1 2024 | $2.11 | +5% |
| Q4 2023 | $2.30 | +21% |
| Q3 2023 | $2.10 | +1.4% |
| Q2 2023 | $2.14 | +6.5% |
| Q1 2023 | $2.01 | +2% |
INMD has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over INMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
INMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $95.6M | 0% |
| Q1 2026 | $82M | +5.3% |
| Q4 2025 | $103.9M | +6.1% |
| Q3 2025 | $93.2M | -28% |
| Q2 2025 | $95.6M | +11% |
| Q1 2025 | $77.9M | -3% |
| Q4 2024 | $97.9M | -23% |
| Q4 2024 | $130.2M | +5.8% |
INMD's revenue has slid since its 2023 peak: $96M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 13% | -11 points |
| Q1 2026 | 12% | -7.8 points |
| Q4 2025 | 25% | -3.4 points |
| Q3 2025 | 22% | -15 points |
| Q2 2025 | 24% | +2.8 points |
| Q1 2025 | 20% | -2.5 points |
| Q4 2024 | 28% | -12 points |
| Q4 2024 | 37% | -0.6 points |
INMD has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over INMD on cash flow, with more consistent year-over-year improvement.
INMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $20.8M | -13% |
| Q1 2026 | $15.2M | +9% |
| Q4 2025 | $24.4M | -24% |
| Q3 2025 | $27M | -21% |
| Q2 2025 | $24M | -43% |
| Q1 2025 | $14M | -42% |
| Q4 2024 | $32.2M | -45% |
| Q4 2024 | $34M | -13% |
INMD's free cash flow has been positive every quarter for seven years: $87M over the past year, down 16% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
INMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -7.1% | -4.6M shares |
| 1 year | -6.7% | -4.3M shares |
| 3 years | -31% | -26.3M shares |
| 5 years | -31% | -26.4M shares |
| Available history | -24% | -18.6M shares |
INMD has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $56.5M |
| Q1 2026 | $31.2M |
| Q4 2025 | $1.9M |
| Q3 2025 | $5.2M |
| Q2 2025 | $28.1M |
| Q1 2025 | $100M |
| Q4 2024 | $119.8M |
| Q4 2024 | $76.6M |
INMD spent $95M buying back its own shares over the past year, down 71% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over INMD on leverage, with a lower net debt burden relative to earnings.
INMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -4.7x | Net Cash |
| Q1 2026 | -3.8x | Net Cash |
| Q4 2025 | -2.6x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -1.5x | Net Cash |
| Q2 2024 | -0.5x | Net Cash |
| Q1 2024 | -0.6x | Net Cash |
| Q4 2023 | -0.6x | Net Cash |
INMD has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
INMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.2 | Neutral |
| Stochastic | 4.9 | Oversold |
INMD's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
INMD PE vs Healthcare Sector
| Metric | INMD | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 26x | 59% below |
| PE % | 35 | 29 | 6 pts above |
INMD is trading at 11x earnings, a 59% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
INMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.8 | 4.4% below |
| 20 week MA | $14.5 | 9.3% below |
| 50 week MA | $14.3 | 7.8% below |
| 100 week MA | $14.9 | 12% below |
| 200 week MA | $20.3 | 35% below |
INMD is in a downtrend: it's below all five of its weekly moving averages, and 35% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
INMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.5 | $23.8 | +22% |
| 2021 | $23.8 | $72.1 | +203% |
| 2022 | $72.1 | $35.4 | -51% |
| 2023 | $35.4 | $22.2 | -37% |
| 2024 | $22.2 | $17.0 | -23% |
| 2025 | $17.0 | $14.6 | -14% |
| 2026 YTD | $14.6 | $13.2 | -9.8% |
INMD has the edge over HIMS on returns for 2026, with the stronger performance.